A RANDOMIZED TRIAL OF DURVALUMAB AND TREMELIMUMAB ¿ PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK, METASTATIC (STAGE IV) SQUAMOUS OR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) - BE.34

ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE0 个研究点目标入组 300 人开始时间: 2021年6月8日最近更新: 2021年8月17日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
入组人数: 300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Si rimanda alle pag. 15/18 del protocollo
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

排除标准

•4.2.1 Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for = 3 years.
•4.2.2 Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (e.g. colitis or Crohn’s disease), diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
•Patients with alopecia.
•Patients with Grave’s disease, vitiligo or psoriasis not requiring systemic treatment (within the last 2 years).
•Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement.
•4.2.3 History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy or grade = 3 infusion reaction.
•4.2.4 Live attenuated vaccination administered within 30 days prior to randomization.
•4.2.5 History of hypersensitivity to durvalumab or tremelimumab or any excipient. Patients who have received other treatment or other antibodies must not have had intolerable toxicity or required steroids to manage toxicity.
•4.2.6 Mean QT interval corrected for heart rate using Fridericia’s formula (QTcF) = 470 msec in screening ECG measured using standard institutional method or history of familial long QT syndrome.
•4.2.7 Patients who have untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if now controlled, should have a LVEF = 45%. (Note: patients with uncomplicated controlled hypertension do not require LVEF measurement in the absence of other significant cardiac history)
•4.2.8 Concurrent treatment with other investigational drugs or anti-cancer therapy
•4.2.9 Patients with untreated brain or meningeal metastases are not eligible. Patients with treated CNS disease who have radiologic AND clinical evidence of stable brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are eligible providing that they are asymptomatic and do not require corticosteroids (must have discontinued steroids at least 1 week prior to randomization).
•4.2.10 Pregnant or Lactating Women:
•Women of childbearing potential must have a pregnancy test (urine or serum) proven negative within 14 days prior to randomization. If urine test is positive, pregnancy testing may then include an ultrasound to rule-out pregnancy if a false-positive is suspected. For example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumour production of hCG, as seen with some cancers. Patient will be considered eligible if an ultrasound is negative for pregnancy. Men an

研究者

发起方

ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE

相似试验

进行中（未招募）

2 期

Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)ung Cancer MetastaticLung Cancer MetastaticCancer - Lung - Non small cell

ACTRN12617001468314HMRC Clinical Trials Centre53

进行中（未招募）

1 期

EUCTR2017-001538-25-DEAIO-Studien-gGmbH128

进行中（未招募）

1 期

Rad-IOMuscle invasive bladder cancerMedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864

EUCTR2018-003520-37-GBniversity of Birmingham159

已完成

2 期

on small cell lung cancer trial of durvalumab and tremelimumab in advanced epidermal growth factor receptor (EGFR) mutant disease.EGFR mutant advanced non small cell lung cancer.Cancer - Lung - Non small cell

ACTRN12618001742268niversity of Sydney100

进行中（未招募）

1 期

Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability.The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classification 8th edition), without distant metastases (cM0).The study requires central confirmation of tumor molecular status of microsatellite instability and dMMR by both immunohistochemistry and multiplex polymerase chain reaction, and EBV-negative status by silver-in situ hybridization.MedDRA version: 20.0Level: LLTClassification code 10073379Term: Tubular adenocarcinoma gastricSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10073378Term: Signet-ring cell adenocarcinoma gastricSystem Organ Class: 100000004864

EUCTR2020-003440-92-ITG.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST31